Safety, pharmacokinetics and pharmacodynamics of TQC3721, an innovative, dual PDE3 and PDE4 inhibitor, in healthy subjects and patients with chronic obstructive pulmonary disease: Randomised, double-blind, placebo-controlled phase I and IIa clinical trials.

In 30 seconds

This study evaluated the safety, pharmacokinetics, and pharmacodynamics of TQC3721, a dual PDE3 and PDE4 inhibitor, in healthy subjects and COPD patients through randomized, double-blind, placebo-controlled phase I and IIa trials. TQC3721 demonstrated significant bronchodilation, with peak FEV₁ improvements of 186 to 272 ml after 4 weeks of treatment.

Key findings

• TQC3721 was rapidly absorbed with a median T max of 0.25 to 0.5 h.
• In COPD patients, FEV₁ improvements ranged from 186 to 272 ml after 4 weeks.
• TQC3721 showed a favourable safety profile in both healthy subjects and COPD patients.
• Bronchodilation effects were sustained over 12 h post-administration.

Why it matters

The findings suggest that TQC3721 could offer a new therapeutic option for COPD, combining bronchodilation and anti-inflammatory effects, which may improve patient outcomes.